Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012.

Bonadies, Nicolas; Feller, Anita; Rovó, Alicia; Ruefer, Axel; Blum, Sabine; Gerber, Bernhard; Stuessi, Georg; Benz, Rudolf; Cantoni, Nathan; Holbro, Andreas; Schmidt, Adrian; Lehmann, Thomas; Wilk, C Matthias; Arndt, Volker (2017). Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012. Cancer epidemiology, 46, pp. 85-92. Elsevier 10.1016/j.canep.2016.12.005

[img] Text
NB_Trends of classification, incidence, mortality and survival of MDS.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (694kB) | Request a copy

Myelodysplastic syndromes (MDS) are emerging disorders of the elderly with an increasing burden on healthcare systems. He we report on the first population-based, epidemiological analysis of patients diagnosed with MDS in Switzerland between 2001 and 2012. The aim of this study was to characterize the extent and limitations of currently available population-based, epidemiological data and formulate recommendations for future health services research. The investigated outcomes comprised trends of annual case frequency, classification of morphological subtypes, incidence, mortality and survival. Annual case frequency increased by 20% (from 263 to 315 cases per year), whereas age-standardized incidence-/mortality-rates remained stable (2.5/1.1 per 100'000 person-years). This observation reflects population growth as well as higher diagnostic awareness and not an increase of age-specific risk. However, it will inevitably influence the future prevalence of MDS and the impact on healthcare systems. Reporting of classification in MDS subtypes was poor with modest improvement from 20% to 39% and increased awareness for mainly higher-risk diseases. Relative survival for all patients at 5-years (RS) ranged between 37 and 40%. Significant better RS was found for younger compared to older higher-risk MDS patients (48% vs. 17%), reflecting the effect of allogeneic hematopoietic stem-cell transplantation. However, no survival advantage was found in elderly patients after introduction of hypomethylating agents as standard for care in this patient group. Our data is in line with results from other MDS and cancer registries. It allows formulating recommendations for future collaborative health services research on MDS patients with national and international partners.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Unit Childrens Hospital > Forschungsgruppe Hämatologie (Erwachsene)

UniBE Contributor:

Bonadies, Nicolas and Rovó, Alicia

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1877-7821

Publisher:

Elsevier

Language:

English

Submitter:

Katrin Kölliker-Schütz

Date Deposited:

13 Apr 2017 12:11

Last Modified:

11 Sep 2017 19:38

Publisher DOI:

10.1016/j.canep.2016.12.005

PubMed ID:

28056392

Uncontrolled Keywords:

Classification; Incidence; Mortality; Myelodysplastic syndromes; Population based cancer registries; Survival / Bonadies Nicolas / Rovó Alicia

BORIS DOI:

10.7892/boris.93141

URI:

https://boris.unibe.ch/id/eprint/93141

Actions (login required)

Edit item Edit item
Provide Feedback